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The purpose of this study is to determine the toxicity and efficacy of temozolomide (TMZ) p.o. followed by subcutaneous (s.c.) low-
dose interleukin-2 (IL2), granulocyte–monocyte colony stimulating factor (GM-CSF) and interferon-a 2b (IFNa) in patients with
metastatic melanoma. A total of 74 evaluable patients received, in four separate cohorts, escalating doses of TMZ (150–250mgm
 2)
for 5 days followed by s.c. IL2 (4MIUm
 2), GM-CSF (2.5mgkg
 1) and IFNa (5 MIU flat) for 12 days. A second identical treatment
was scheduled on day 22 and cycles were repeated in stable or responding patients following evaluation. Data were analysed after a
median follow-up of 20 months (12–30 months). The overall objective response rate was 31% (23 out of 74; confidence limits 20.8–
42.9%) with 5% CR. Responses occurred in all disease sites including the central nervous system (CNS). Of the 36 patients with
responding or stable disease, none developed CNS metastasis as the first or concurrent site of progressive disease. Median survival
was 252 days (8.3 months), 1 year survival 41%. Thrombocytopenia was the primary toxicity of TMZ and was dose- and patient-
dependent. Lymphocytopenia (grade 3–4 CTC) occurred in 48.5% (34 out of 70) fully monitored patients following TMZ and was
present after immunotherapy in two patients. The main toxicity of combined immunotherapy was the flu-like syndrome (grade 3) and
transient liver function disturbances (grade 2 in 20, grade 3 in 15 patients). TMZ p.o. followed by s.c. combined immunotherapy
demonstrates efficacy in patients with stage IV melanoma and is associated with toxicity that is manageable on an outpatient basis.
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Metastatic melanoma is a highly chemotherapy-resistant tumour.
The best-known single agent dacarbazine (DTIC) achieves a 15–
20% response rate with a median survival of 6–7 months. The
addition of other cytotoxic agents does not improve survival
(Lakhani et al, 1990; Chapman et al, 1999). Therefore, interest has
shifted to immunotherapy as malignant melanoma is considered to
be an immunogenic tumour. Although immunotherapy with high-
dose IL2 can induce durable complete remissions in a small
proportion of patients (Legha et al, 1997), the toxicity requires
treatment on an in-patient basis with transfer to the intensive care
if toxicity is severe.
Recently, a combination of chemo- and immunotherapy has
been investigated in several phase II studies (Khayat et al, 1993;
Legha et al, 1998; O’Day et al, 1999; Richards et al, 1999) with
responses of 40–60%. However, in a recent phase III trial, survival
did not improve with the addition of high-dose IL2 and IFNa to
chemotherapy compared to chemotherapy alone (Rosenberg et al,
1999).
The occurrence of brain metastasis is a major clinical issue. Its
incidence is up to 75% in patients who die from metastatic
melanoma (Amer et al, 1978). Brain metastases occur as the first
site of progression in a significant proportion of patients with a
CR, and in a large majority of patients with a PR following
systemic treatment with DTIC or cisplatin as neither of these
agents cross the blood–brain barrier (Legha et al, 1998; O’Day et al,
1999).
Temozolomide (TMZ), a prodrug of the alkylating agent 5-(3
methyltriazen-1-yl) imidazole-4-carboximide (MTIC), is a novel
alkylating agent that is similar to DTIC. However, unlike DTIC, it
is converted to MTIC under physiologic conditions, and oral
administration is possible (Amer et al, 1978; Stevens et al, 1987).
TMZ has comparable activity to DTIC in melanoma (Middleton
et al, 2000). In addition, it penetrates the blood–brain barrier,
which can be beneficial in preventing or treating CNS metastasis.
One of the concerns with TMZ therapy is the occurrence of
lymphocytopenia, which could have detrimental effects in an
immunogenic tumour such as melanoma. Therefore, we evaluated
the toxicity and efficacy of escalating doses of oral TMZ followed
by subcutaneous injections of low-dose IL2, GM-CSF and IFNa in a
phase I/II trial in patients with metastatic melanoma.
The feasibility and dosing of this combination of immunother-
apeutic agents was first tested in a phase I trial (De Gast et al,
2000). The combination of these three cytokines was based on the
theory of improving antigen presentation with GM-CSF, expanding
and activating T cells (LD-IL2+GM-CSF), increasing effector cell
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lfunction (IFNa) and immunosensitising tumour cells by increased
expression of HLA and adhesion molecules (IFNa). This treatment
can be given on an outpatient basis, which is an important factor
for patients, especially those with a poor prognosis.
PATIENTS AND METHODS
Patients
The study was approved by the Protocol Review Committee of the
Netherlands Cancer Institute, which dealt with the ethical aspects.
All patients entered on study had metastatic melanoma confirmed
by biopsy or cytology and signed informed consent before
registration. Eligibility criteria were patients older than 18 years
who were able to give informed consent, WHO performance scores
of 0,1 or 2, measurable disease, adequate bone marrow function
(leucocytes X4.0nl
 1, platelets 4100nl
 1), renal function (crea-
tinine o180mmoll
 1) and liver function (transaminases, alkaline
phosphatase o3 ULN, in case of liver metastases o5 ULN,
bilirubin within normal limits). Patients with brain metastases
o2cm could be included if there was no risk of serious
complications.
Exclusion criteria included serious cardiac, pulmonary or
metabolic disease, pregnancy or lactation, concurrent systemic
immunosuppressive treatment, previous or present autoimmune
disease, a-HIV antibodies, symptomatic cerebral oedema and any
other uncontrolled cancer. No previous chemotherapy or im-
munotherapy except adjuvant IFNa was allowed.
Characteristics of the 74 evaluable patients are listed in Table 1.
Treatment
Chemotherapy TMZ (Temodal, provided by Schering-Plough,
Maarssen, The Netherlands) was given orally for 5 days at a dose of
150, 200 and 250mgm
 2 in cohorts of 6, 18 and 18 patients,
respectively. Following evaluation of the dose levels, the following
cohort of 32 patients received 200mgm
 2 in the first cycle with
dose adjustment in subsequent cycles depending on the degree of
myelosuppression.
Immunotherapy Low-dose IL2 (Aldesleukin, Proleukin
R 4
MIUm
 2, provided by Chiron BV, Amsterdam, The Netherlands),
granulocyte–monocyte colony stimulating factor (GM-CSF) (Mol-
gramostim, Leukomax
R 2.5mgkg
 1, Schering-Plough, Maarssen,
(The Netherlands) and interferon-a-2b IFNa (Intron A
R 5MIU,
Schering-Plough, Maarssen, The Netherlands)) were given as
subcutaneous injections for 12 days in the abdominal wall, left
leg and right leg, respectively. The right or left arm was used if
lymphadenectomy had been performed in one or both lower limbs.
The first cycle of combined immunotherapy was initiated on an
in-patient basis with the MTD found in the phase I study (De Gast
et al, 2000). Patients were observed for toxicity and discharged
after 2 or 3 days when the drug dosage was deemed safe for home
(outpatient) administration. If grade 4 fever with hypotension or
any other unacceptable toxicity was seen, the dose of IL2 was
reduced by 50%. Subsequent cycles were all given on an outpatient
basis.
Dose modification In the third cohort (250mgm
 2) the dose of
TMZ was reduced to 200mgm
 2 for grade 3 myelosuppression or
to 150mgm
 2 for grade 4 myelosuppression. TMZ was increased
in the fourth cohort from 200 to 250mgm
 2 in the second or
subsequent cycles if no myelosuppression occurred, or to
225mgm
 2 if CTC grade 1 myelosuppression occurred. The dose
was maintained if grade 2 myelosuppression occurred and reduced
to 150mgm
 2 if grade 3 or 4 reversible myelosuppression was
present.
The IL2 dose was reduced from 4 to 2MIUm
 2 if grade 4 fever
with hypotension occurred or when persistent severe malaise,
diuretic insensitive weight gain 45% or grade 3 liver dysfunction
occurred. GM-CSF was stopped if leukocytes increased above
40nl
 1.
Supportive measures Patients routinely received granisetron 1mg
orally 1h prior to TMZ p.o. to prevent nausea and vomiting.
Magnesium oxide 500mg b.i.d./t.i.d. was given routinely to treat
granisetron-induced constipation.
Prior to the first administration of immunotherapy, patients
received 0.5l of NaCl 0.9% intravenously. Paracetamol 1g p.o. was
administered 1h following the injections, 1g at the onset of chills
and 1g 4h later and subsequently when necessary up to
4000mgday
 1.
Metoclopramide tablets 10 or 20mg suppositories were used to
treat or prevent nausea during the immunotherapy phase. No
systemic steroids were permitted except in emergency situations.
Evaluation Prior to treatment, physical examination (PE),
intravenous contrast-enhanced computer tomography (CT) scans
of chest, abdomen and pelvis, magnetic resonance imaging (MRI)
of the brain and radioactive technetium scan of the bone were
performed to determine the extent of the disease. In addition, an
electrocardiogram and blood tests for haematology, liver and renal
function and an HIV antibody test were performed.
Complete blood counts, differential WBC count, platelet count,
serum S100, liver and renal function tests were done at the start of
treatment, following 5 days of TMZ, and were repeated after weeks
1 and 3 of the immunotherapy during each cycle. In addition, the
absolute number of T cells (CD3
+, CD4
+, CD8
+), NK cells (CD3-
CD16+56+), monocytes (CD14+), B cells (CD19+) and activated
cells (double staining with HLA-DR) were determined with
monoclonal antibodies using the FACS scan flow cytometer as
described previously. Soluble IL2-receptor (sIL2R, Eurogenetics,
Table 1 Patient characteristics (n=74)
Age (years)
Median 45
Range 21–70
WHO performance status
05 7
11 3
24
Male:female ratio 44:30
Sites of disease
CNS 13
Liver 25
Bone 21
CNS/liver/bone 40 (54%)
M1a 15
M1b 9
M1c 50
No. of metastatic sites
One 20
Two 26
More than two 28
Primary tumour
Skin 66
Ocular 4
Mucosa 4
M1a=patients with distant skin, subcutaneous or lymph node metastases;
M1b=patients with lung metastases; M1c=patients with other visceral sites of
metastasis or increased LDH (AJCC staging system); CNS=central nervous system.
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lTessenderlo, Belgium) and sCD8 (T Cell Diagnostics, Cambridge
MA, USA) were assayed by ELISA as described (De Gast et al,
2000).
Response evaluation Physical examination, CT scans and MRI of
the brain were repeated after every 2 cycles in week 7. Metastatic
disease was quantified as the sum of products of the perpendicular
diameters of marker lesions. All measurable lesions on CT scans
were used as marker lesions, and up to 10 subcutaneous nodules.
Responses were defined as follows: complete response (CR):
disappearance of all measurable disease; partial response (PR):
50% or more reduction in measurable disease with no new lesions;
stable disease (SD): less than 25% change in measurable disease
and no new lesions; progressive disease (PD): 25% or more
increase in measurable disease or the appearance of new lesions, or
lost to follow-up owing to deteriorating clinical condition.
Responses must have been confirmed by post-treatment evaluation
6 weeks later.
In patients with PD, treatment was stopped and palliative
radiotherapy considered. In patients with SD another two cycles
were given.
If tumour regression occurred, cycles were continued with a
response evaluation every two cycles. If a CR was observed, two
subsequent consolidation cycles were given.
Statistics Survival curves were constructed using the Kaplan–
Meier technique using the initiation of chemotherapy as the
starting point. Levels of circulating cells in peripheral blood and of
cytokines measured at various time points and in various groups
were compared using Student’s t-test. P-values o0.05 were
considered significant.
RESULTS
Tumour response
A total of 77 patients were entered into the trial in a single
institution (Netherlands Cancer Institute, Amsterdam). Three
patients were subsequently excluded. One patient with lymph
node enlargement appeared to have Hodgkin’s disease and the
primary tumour was a dysplastic nevus. Two patients did not start
with immunotherapy (one because of rapid progressive disease
and the other because of large brain metastases). A total of 74
patients received at least 1 week of immunotherapy following
chemotherapy and were evaluable for response. Two patients
stopped immunotherapy after 7 days because of rapidly progres-
sive disease or severe malaise. Another eight patients stopped
treatment after one full cycle of chemoimmunotherapy because of
progressive disease (n¼7) or severe malaise (n¼1). None of the
patients received prior chemotherapy and seven had received
adjuvant IFNa.
Responses in the 74 evaluable patients are shown in Table 2. The
overall objective response rate was 31% (23 out of 74, confidence
limits 20.8–42.9%). CR was seen in four patients following either
the second or fourth cycle of therapy. One patient with a PR and an
isolated iliac lymph node (LN) underwent resection of the LN
resulting in a surgical CR. Two patients with isolated lung
metastasis, who remained stable after four cycles of chemoimmu-
notherapy, underwent (bi)lobectomy.
Two patients with initial CRs remained tumour free (30+
months) as did one patient after lobectomy (24+ months). In the
other patient with lobectomy, an isolated LN metastasis was
removed 6 months later and two isolated pancreatic metastases 12
months later (0S 34+ months).
Survival from the start of treatment is shown in Figure 1. Median
survival is 252 days and the 1 year survival is 41%.
Central nervous system (CNS) metastases
CNS metastases were present prior to treatment in 13 patients. One
patient with a CR in the brain had a lesion of 7.5mm that
disappeared completely. When the mediastinal mass (PR) began to
grow again, the brain metastasis remained in remission.
One patient with neoplastic meningitis, who presented with a
confusional state, headache, cranial nerve dysfunction and a
marked increase of malignant cells in the cerebrospinal fluid, had
relief of all symptoms and signs following therapy. Relapse of this
meningitis occurred as the first sign of progression, 7 months after
the initiation of treatment. Two patients had SD both in and
outside of the CNS.
To date, none of the 36 patients with CR, PR or SD have
developed CNS metastasis as the first or concurrent site of
progression.
Toxicity TMZ
None of the six patients with 150mgm
 2 TMZ 5 or of the first
series of 18 patients with 200mgm
 2 TMZ developed CTC grade 3
Table 2 Response evaluation
Response No. of patients Median PFS (months) Median OS (months)
CR 4 4, 9, 30+, 30+ 13, 15, 32+, 32+
PR 19 1 sCR (iliacal LN) 5 12 (range 4.5–30+)
SD 13 2 sCR (2 lobectomy) 5 12 (range 7–34+)
PD 38 – 4.5 (range 1–11)
Total 74
sCR=surgical CR; LN=lymph node.
N98TIM: Survival from start of treatment
Number of days from start of treatment
1.00
0.75
0.50
0.25
0.00
0 200 400 600 800
Figure 1 Survival from start of treatment of 74 evaluable patients.
Median survival is 252 days.
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lor 4 thrombocytopenia. However, nine out of 18 patients (50%)
receiving 250mgm
 2 TMZ 5 developed grade 3–4 thrombocy-
topenia as shown in Table 3. Characteristically, thrombocytopenia
began on day 16 (d12–d18) and resolved on day 29 (d24–d32).
Bleeding did not occur. Platelet transfusions were given to five
patients. Based on these results, patients in the fourth cohort
received 200mgm
 2 TMZ in the first cycle and when appropriate
had a dose adjustment in subsequent cycles. Three of 32 patients
(9%) developed grade 3 or 4 thrombocytopenia at this dose.
Patients with grade 3 or 4 thrombocytopenia generally also
developed grade 2 or 3 granulocytopenia. Of the 50 patients who
received TMZ 200mgm
 2 for 5 days in the first cycle, three (6%)
developed grade 3 or 4 thrombocytopenia. A dose reduction of
TMZ in subsequent cycles always prevented grade 3 or 4
thrombocytopenia.
Lymphocytopenia grade 3 or 4 occurred in 50% of the patients
receiving X200mgm
 2 TMZ 5 without a clear effect of the TMZ
dose. Severe lymphocytopenia (grade 3 or 4) was present in 13%
(nine out of 70) of patients prior to treatment, increased to 49%
(34 out of 70) after 5 days of TMZ and was nearly absent after
immunotherapy (3%, two out of 70) (Table 4).
Lymphocytopenia prior to treatment was not correlated with
response, nor did the number of lymphocytes following immuno-
therapy (results not shown).
Toxicity immunotherapy
All patients developed flu-like syndrome, fatigue and anorexia. A
majority also had transient liver function disturbances, mostly
transaminase or alkaline phosphatase elevations (23 grade 1, 20
grade 2, 15 grade 3, 0 grade 4). In 39 out of 74 (52.9%) patients, the
IL2 dose was decreased to 2MIUm
 2 because of grade IV fever
with (rapidly reversible) hypotension (n¼17), severe fatigue
(n¼7) or grade 3 liver function disturbances (n¼15). None of
the patients died of treatment-related toxicity and none were
treated with steroids.
Immunologic evaluation
Although depression of CD3
+ T cells did occur following 5 days of
TMZ, it did not prevent activation of CD3, CD4 or CD8+ T cells,
nor the expansion of NK cells by immunotherapy (Figure 2). B-cell
numbers were not influenced (results not shown). There was no
relation between lymphocyte number and activation prior to or
following immunotherapy and response to treatment (data not
shown).
Similar to the activated T-cell numbers, soluble IL-2R and
soluble CD8 showed no decrease following 5 days TMZ treatment
(sIL2R 631 and 835 Uml
 1, respectively, before and after TMZ,
and sCD8 288 and 342Uml
 1). A significant increase was seen
after 12 days of immunotherapy (sIL2R increased to 9066Uml
 1;
sCD8 increased to 860Uml
 1). No correlation was found with
response or survival (data not shown).
DISCUSSION
Thrombocytopenia was the dose-limiting toxicity (DLT) of TMZ
and combined subcutaneous immunotherapy with low-dose IL2,
GM-CSF and IFNa, and it was dose- and patient-dependent. The
highest dose (250mgm
 2 5) caused grade 3–4 thrombocytope-
nia in nine out of 18 patients (50%) vs three out of 50 patients (6%)
starting with 200mgm
 2. Several phase I trials of TMZ in patients
with advanced cancer also demonstrated myelosuppression,
Table 3 Grade 3–4 CTC toxicity according to cohorts/dose levels
150mgm
 2a 200mgm
 2a 250mgm
 2a 200mgm
 2 adj.
a,b
No. of patients 6 18 18 32
Thrombocytopenia
Grade 3 0 0 5 1
Grade 4 0 0 4 2
Lymphocytopenia
Grade 3 2 5 8 12
Grade 4 0 2 3 3
aOral administration for 5 days;
bDose adjustments took place in the following cycles according to the degree of myelosuppression.
Table 4 Lymphocytopenia before and after treatment of 70 patients
fully monitored
Before
start
After 5 days
TMZ
a
After
immunotherapy
Grade 0 (>2.0nl
 1)1 7 3 4 5
Grade 1 (1.51–2.0) 20 8 15
Grade 2 (1.01–1.5) 24 25 8
Grade 3 (0.51–1.0) 9 27 2
Grade 4 (p0.5) 0 7 0
aAfter 5 days oral TMZ.
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Figure 2 Lymphocyte subsets and activation before start (day 1),
following 5 days of TMZ (day 6), following 12 days of immunotherapy (day
17) and prior to start of the second cycle (day 22). T cell (CD3) number
decreased by TMZ, but was corrected following immunotherapy. Activated
T cells (CD3/DR), its subsets (CD4/DR and CD8/DR) as well as the
number of NK cells increased significantly following immunotherapy.
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lespecially thrombocytopenia, as the DLT (Dhodapkar et al, 1997;
Hammond et al, 1999; Newlands et al, 1992; O’Reilly et al, 1993).
The thrombocytopenia was always transient and bleeding was not
observed. Platelet transfusions were given to five patients. A dose
reduction of TMZ prevented severe thrombocytopenia in all
patients in subsequent cycles.
An interesting, previously not well-documented phenomenon
was severe (grade 3 or 4) lymphocytopenia, present in 13% (nine
out of 70) of patients before initiation of TMZ, which increased to
49% (34 out of 70) following 5 days of TMZ. To correct the
expected lymphocytopenia by TMZ in such an immunogenic
tumour as malignant melanoma, we administrated combined
immunotherapy with GM-CSF, low-dose IL2 and IFNa s.c. for 12
days in a dosing schedule determined in a phase I study (De Gast
et al, 2000). The combination of GM-CSF and low-dose IL2 was
given in order to activate and expand antigen-presenting cells and
T cells. Moreover, we aimed to avoid the toxic effects of the
activation and expansion of NK cells by high-dose IL2. As NK cells
have an IL2-receptor (IL2R) of intermediate affinity, we expected
no NK cell activation with this low dose of IL2 in contrast to T
cells, which have an IL2R of high affinity when activated (Caligiuri
et al, 1990; Nagler et al, 1990). Following immunotherapy, severe
lymphocytopenia was only present in 3% (two out of 70) of
patients. Whether this is only an effect of the immunotherapy or
reflects also a spontaneous recovery following TMZ is not clear.
In addition to lymphocyte recovery, lymphocyte activation was
not inhibited when TMZ was followed by immunotherapy as
indicated by the increase of HLA-DR-expressing T cells and
increased levels of sIL2R and sCD8. A moderate increase in the
number of NK cells was observed with the low-dose IL2 combined
with GM-CSF.
The toxicity of combined immunotherapy consisted of flu-like
syndrome, fatigue, anorexia and transient liver function distur-
bances. Since the expansion of NK cell numbers as seen in the
phase I study was clearly dependent on the IL2 dose (De Gast et al,
2000), we decreased the IL2 dose from 4 to 2MIUm
 2 when
toxicity was severe (grade 3 or 4 CTC), assuming that it was mainly
an IL2 effect. CD4-T-cell activation as reflected in sIL2R levels was
maintained with this dose (De Gast et al, 2000). The IL2 dose was
reduced to 2MIUm
 2 in 39 out of 74 patients. Owing to the
supportive care programme, treatment could be continued on an
outpatient basis in all patients, which is important for this patient
population with a poor prognosis and short survival.
TMZ has shown efficacy in primary brain tumours and
metastatic melanoma in phase II trials (Bleehen et al, 1995; Yung
et al, 1999) However, in a phase III trial, it was not found to be
superior to DTIC (Middleton et al, 2000). In our study, an overall
response rate of 31% (24 out of 74 patients) was achieved with a 1-
year survival of 41% and a median survival of 252 days. The
response rate was higher than that shown for TMZ alone
previously (Middleton et al, 2000). Whether the higher response
is because of dose intensification of TMZ (cycles3 weeks
 1) or the
addition of immunotherapy is unclear. Patient selection is less
likely to be a factor, as our patient population had an extremely
poor prognosis with 450% of patients having CNS, liver or bone
metastases, well-known indicators of poor prognosis (Ryan et al,
1993). Whether subcutaneous combined immunotherapy adds a
survival benefit to monotherapy with TMZ is presently the goal of
a multicentre phase III trial, which is now being conducted in the
Netherlands. In this respect, it may be important that neither the
number of lymphocytes, (activated) T cells or NK cells prior to
start nor those following immunotherapy were correlated with
response. Recently it has been found that lymphocyte numbers
after high dose IL-2 correlated with response (Phan et al, 2001).
We did not find such a correlation in our study.
A major finding of the study was the effect of TMZ on CNS
metastases: in patients with CNS metastases present on MRI, one
out of 13 patients showed a complete disappearance of a brain
metastasis and continued remission when progression occurred at
extracranial sites and one patient demonstrated long-term
regression of meningeal metastases. In previous studies of
chemo-immunotherapy in metastatic melanoma, no response
was observed in brain metastases despite objective tumour
regression at extracranial sites (Legha et al, 1998; O’Day et al,
1999).
Of interest, TMZ might be effective in the prevention of brain
metastases, which is one of the most threatening complications of
advanced melanoma. In this study, brain metastasis did not
develop as the first or concurrent site of progressive disease in
patients with either responsive disease (n¼23) or with stable
disease (n¼13). Two prior published reports have indicated brain
metastasis as a first site of progressive disease in four out of nine
patients with a complete remission (Legha et al, 1998; O’Day et al,
1999). Moreover, in a retrospective case-controlled study of
responders to DTIC or TMZ, it was found that responders to
TMZ developed significantly less CNS relapses than responders to
DTIC (Paul et al, 2002). Importantly, low-dose IL-2 did not appear
to cause signs or symptoms of brain oedema in patients with CNS
disease.
In conclusion, temozolomide p.o. followed by combined
immunotherapy s.c. demonstrates efficacy in patients with stage
IV melanoma and is associated with toxicity manageable on an
outpatient basis.
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